Cargando…

LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS

BACKGROUND: Leptomeningeal metastasis (LM) is an aggressive complication of cancer. No standard therapies exist, although at our institution we commonly use IT topotecan in good-risk patients. We report our experience in patients with HER2+ breast cancer (BC) LM treated with intrathecal (IT) trastuz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trevino, Christopher R, Murthy, Rashmi K, Raghavendra, Akshara Singareeka, Loghin, Monica, Seligman, Christa, Ferguson, Sherise, Kamiya-Matsuoka, Carlos, Harrison, Rebecca, Sinicrope, Kaylyn D, Valero, Vicente, Tummala, Sudhakar, Hess, Kenneth, Tripathy, Debu, de Groot, John, O’Brien, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213336/ http://dx.doi.org/10.1093/noajnl/vdz014.031

Ejemplares similares

LPTO-09. INTRATHECAL TOPOTECAN FOR LEPTOMENINGEAL METASTASIS IN SOLID TUMORS: THE MD ANDERSON EXPERIENCE
por: Sinicrope, Kaylyn D, et al.
Publicado: (2019)

LPTO-01. LEPTOMENINGEAL METASTASIS FROM OVARIAN CARCINOMA TREATED WITH SYSTEMIC HIGH-DOSE METHOTREXATE
por: Coffee, Elizabeth, et al.
Publicado: (2019)

LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY
por: Kumthekar, Priya, et al.
Publicado: (2019)

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
por: Mouabbi, Jason A., et al.
Publicado: (2022)

ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022)

LPTO-06. A NOVEL BRAIN-PERMEANT CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS
por: Deng, Jiaojiao, et al.
Publicado: (2019)

LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY
por: Williams, Nicole, et al.
Publicado: (2019)

LPTO-07. CARCINOEMBRYONIC ANTIGEN OF CEREBROSPINAL FLUID PREDICT PROGNOSIS OF LEPTOMENINGEAL METASTASIS FROM NON-SMALL CELL LUNG CANCER
por: Zhen, Junjie, et al.
Publicado: (2019)

LPTO-05. FACTORS INFLUENCING RISK OF LEPTOMENINGEAL METASTASIS IN BREAST CANCER PATIENTS RECEIVING STEREOTACTIC RADIOSURGERY FOR LIMITED BRAIN METASTASES
por: Zhang, Michael, et al.
Publicado: (2019)

Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer
por: Garber, Haven R., et al.
Publicado: (2022)

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
por: Park, Won-Young, et al.
Publicado: (2016)

Intra‐CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases
por: Jaeckle, Kurt A., et al.
Publicado: (2020)

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
por: Glitza Oliva, Isabella C., et al.
Publicado: (2023)

LPTO-03. IN-VITRO & IN-VIVO CULTURE OF PATIENT (PT) DERIVED CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) FROM MELANOMA TO IDENTIFY NOVEL TREATMENT STRATEGIES
por: Law, Vincent, et al.
Publicado: (2019)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy
por: Mouabbi, Jason A., et al.
Publicado: (2023)

Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma
por: Shackleford, Gregory M., et al.
Publicado: (2019)

48218 Preclinical modeling of BRAF(V600E)/PTEN-/- melanoma leptomeningeal disease (LMD) to assess intrathecal checkpoint blockade
por: Guerrieri, Renato A., et al.
Publicado: (2021)

Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2021)

The Impact of Treatment for Smoking on Breast Cancer Patients’ Survival
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2022)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
por: Lu, Nu T., et al.
Publicado: (2015)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
por: Gulia, Seema, et al.
Publicado: (2016)

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
por: Liu, Shuying, et al.
Publicado: (2023)

Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)
por: Ferguson, Sherise D., et al.
Publicado: (2022)

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
por: Liu, Shuying, et al.
Publicado: (2023)

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
por: Glitza, Isabella C, et al.
Publicado: (2018)

BSCI-08 NEURONAL MIMICRY PROMOTES BREAST CANCER LEPTOMENINGEAL METASTASIS FROM BONE MARROW
por: Whiteley, Andrew, et al.
Publicado: (2022)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
por: Lazaratos, Anna-Maria, et al.
Publicado: (2023)

LptO (PG0027) Is Required for Lipid A 1-Phosphatase Activity in Porphyromonas gingivalis W50
por: Rangarajan, Minnie, et al.
Publicado: (2017)

Pulsed Erlotinib as Sole Treatment of Leptomeningeal Carcinomatosis: Can We Avoid the Use of Intrathecal Therapy?
por: Santhosh-Kumar, Cheruppolil R., et al.
Publicado: (2014)

A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer
por: Geng, Di, et al.
Publicado: (2022)

Intrathecal methotrexate in combination with systemic chemotherapy in glioblastoma patients with leptomeningeal dissemination: A retrospective analysis
por: Kang, Xun, et al.
Publicado: (2022)

CERN: Minus omega
Publicado: (1997)

Stabilizing the minus ends?
por: Tuma, Rabiya S.
Publicado: (2005)

Minus 15 Prozent
por: Freisleben, Christian F.
Publicado: (2021)

Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report
por: García, Francisco José Valdivia, et al.
Publicado: (2020)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

LPTO-04. GENERATION AND CHARACTERIZATION OF PATIENT-DERIVED PRECLINICAL MODELS FROM TUMOR CELLS ISOLATED FROM CEREBROSPINAL FLUID
por: Offin, Michael, et al.
Publicado: (2019)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
por: Carausu, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2fqvoaplle8segc31b4t6b1qp0